Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation

S Stephanie J. Lee B Brent Logan (2CIBMTR/Medical College of Wisconsin, Milwaukee, United States) M Mary M. Horowitz (2Division of Hematology and Oncology, Department of Medicine, Center for International Blood and Marrow Transplant Research/Medical College of Wisconsin, Milwaukee, WI) J Jason G. Dehn (NMDP, Minneapolis, MN) J Joseph Pidala (1H. Lee Moffitt Cancer and Research Institute, Tampa, United States) M Michael R. Grunwald (12Levine Cancer Institute, Atrium Health, Charlotte, NC) P Peter Westervelt (11Massachusetts General Hospital, Boston, United States) N Nosha Farhadfar (6Sarah Cannon Transplant & Cellular Program at Methodist Hospital, San Antonio, United States) W William J. Hogan (Division of Hematology, Mayo Clinic Rochester, Rochester, MN) A Asad Bashey (9BMT Program at Northside Hospital, Atlanta, United States) B Brandon Hayes-Lattin (1Oregon Health and Science University, Portland, United States) L LaQuisa Hill (9Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX) C Claudio Brunstein (1Cleveland Clinic Foundation, Department of Hematology and Medical Oncology, Cleveland, United States) S Sally Arai S Samer A. Srour (Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX) H Heather Symons (25Johns Hopkins Hospital, Division of Pediatric Oncology, Department of Oncology, Baltimore, United States) J Joseph Uberti (1Karmanos Cancer Institute, Detroit, United States) S Sumithira Vasu (29Department of Internal Medicine, The Ohio State University, Columbus, OH) I Iskra Pusic (6Washington University in St. Louis School of Medicine, St. Louis, United States) M Mark Juckett (8University of Minnesota, Minneapolis, United States) E Eric Leifer N Naya He (Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI) S Steven Devine (24National Marrow Donor Program, Minneapolis, United States) B Bronwen E. Shaw (CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI) S Stefan O. Ciurea (University of California-Irvine, Irvine, CA)

Abstract

PURPOSE The likelihood of finding a human leukocyte antigen (HLA)–matched unrelated donor (MUD) for hematopoietic cell transplantation can be predicted using a donor search prognosis score. Patients without a MUD may use alternative donors (haploidentical related, mismatched unrelated, or umbilical cord blood). METHODS This multicenter biological assignment trial was conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1702). Eligibility criteria were broad to mirror clinical practice. The primary end point was 2-year survival from evaluability and compared between those Very Likely (>90%) and Very Unlikely (<10%) to find a MUD. All other patients, Less Likely to find a MUD, were enrolled in an observational arm. Transplant outcomes were compared for all three groups. RESULTS A total of 1,751 evaluable patients at 47 centers were Very Likely (54.7%), Less Likely (29.5%), and Very Unlikely (15.8%) to identify a MUD. Survival did not differ in univariate (hazard ratio [HR], 1.00 [95% CI, 0.82 to 1.21]; P = .98) or multivariate (HR, 1.07 [95% CI, 0.86 to 1.33]; P = .56) analyses between the Very Unlikely and Very Likely groups, measured through 2 years from the beginning of a search for a MUD or alternative donor. Of the transplanted patients (n = 1,179), MUD was used for 94% of the Very Likely, 38% of Less Likely, and 9% of Very Unlikely patients. Multivariate analyses showed no differences in relapse, treatment-related mortality, disease-free survival, and acute and chronic graft-versus-host diseases for the three search prognosis groups after transplantation. CONCLUSION Using a donor search prognosis strategy to prioritize an alternative donor for patients Very Unlikely to find a MUD resulted in survival and transplant outcomes that were not statistically different compared with those Very Likely to find a MUD.

Article Details

Volume / Issue Vol. 43, Issue 31
Published November 01, 2025
Pages 3369-3380
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (25)

S

Stephanie J. Lee

B

Brent Logan

2CIBMTR/Medical College of Wisconsin, Milwaukee, United States

M

Mary M. Horowitz

2Division of Hematology and Oncology, Department of Medicine, Center for International Blood and Marrow Transplant Research/Medical College of Wisconsin, Milwaukee, WI

J

Jason G. Dehn

NMDP, Minneapolis, MN

J

Joseph Pidala

1H. Lee Moffitt Cancer and Research Institute, Tampa, United States

M

Michael R. Grunwald

12Levine Cancer Institute, Atrium Health, Charlotte, NC

P

Peter Westervelt

11Massachusetts General Hospital, Boston, United States

N

Nosha Farhadfar

6Sarah Cannon Transplant & Cellular Program at Methodist Hospital, San Antonio, United States

W

William J. Hogan

Division of Hematology, Mayo Clinic Rochester, Rochester, MN

A

Asad Bashey

9BMT Program at Northside Hospital, Atlanta, United States

B

Brandon Hayes-Lattin

1Oregon Health and Science University, Portland, United States

L

LaQuisa Hill

9Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX

C

Claudio Brunstein

1Cleveland Clinic Foundation, Department of Hematology and Medical Oncology, Cleveland, United States

S

Sally Arai

S

Samer A. Srour

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

H

Heather Symons

25Johns Hopkins Hospital, Division of Pediatric Oncology, Department of Oncology, Baltimore, United States

J

Joseph Uberti

1Karmanos Cancer Institute, Detroit, United States

S

Sumithira Vasu

29Department of Internal Medicine, The Ohio State University, Columbus, OH

I

Iskra Pusic

6Washington University in St. Louis School of Medicine, St. Louis, United States

M

Mark Juckett

8University of Minnesota, Minneapolis, United States

E

Eric Leifer

N

Naya He

Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI

S

Steven Devine

24National Marrow Donor Program, Minneapolis, United States

B

Bronwen E. Shaw

CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI

S

Stefan O. Ciurea

University of California-Irvine, Irvine, CA